

U.S.S.N. 08/323,060  
Filed: October 14, 1994  
AMENDMENT

*In the Claims*

1. (previously presented) A method for inhibiting microvascular bleeding at a site in a patient exhibiting microvascular bleeding comprising administering to the patient a compound in a pharmaceutically acceptable carrier in an effective amount to prevent anticoagulation by greater than 90% of activated protein C in human plasma, wherein the compound is an inhibitor of an anticoagulant selected from the group consisting of protein C, antithrombin III, heparin cofactor II, thrombomodulin and tissue factor pathway inhibitor.
2. (previously presented) The method of claim 1 wherein the anticoagulant is protein C.
3. (previously presented) The method of claim 1 wherein the inhibitor is administered systemically.
4. (original) The method of claim 1 wherein the inhibitor is administered topically.
5. (previously presented) The method of claim 1 further comprising topically administering at the site of the bleeding a coagulant.
6. (original) The method of claim 5 wherein the coagulant is selected from the group consisting of thrombin and tissue thromboplastin.
7. (currently amended) ~~The method of claim 2 wherein the inhibitor is~~ A method for inhibiting microvascular bleeding at a site in a patient exhibiting microvascular bleeding comprising administering to the patient an antibody to protein C in a pharmaceutically acceptable carrier in an effective amount to prevent anticoagulation by greater than 90% of activated protein C in human plasma ~~an antibody to protein C.~~

U.S.S.N. 08/323,060  
Filed: October 14, 1994  
AMENDMENT

8. (currently amended) The method of claim 7 ~~wherein the inhibitor is administered systemically~~ further comprising the step of topically administering a coagulant at the site of bleeding.
9. (previously presented) The method of claim 8 wherein the topically administered coagulant is selected from the group consisting of thrombin in a dosage of between approximately 1000 and 10,000 units and tissue factor in a dosage of between approximately 0.1 and 10 mg.
10. (canceled)
11. (previously presented) The method of claim 1 wherein the inhibitor is administered to a burn patient.
12. (previously presented) The method of claim 1 wherein the inhibitor is administered to a patient with tissue or skin grafts.
13. (previously presented) The method of claim 1 wherein the inhibitor is administered to a patient with cerebral contusions.
14. (canceled)
15. (canceled)
16. (canceled)
17. (canceled)
18. (canceled)
19. (original) The method of claim 4 further comprising the step of topically administering a coagulant at the site of bleeding.

U.S.S.N. 08/323,060  
Filed: October 14, 1994  
AMENDMENT

20. (currently amended) ~~The method of claim 3 wherein the inhibitor~~ A method for inhibiting microvascular bleeding at a site in a patient exhibiting microvascular bleeding comprising systemically administering to the patient a monoclonal antibody to protein C which blocks protein C activation in a pharmaceutically acceptable carrier in an effective amount to prevent anticoagulation by greater than 90% of activated protein C in human plasma is a monoclonal antibody immunoreactive with protein C and blocking protein C activation.

21. (currently amended) The method of claim 20 wherein the ~~inhibitor~~ antibody is HPC-4, deposited with the American Type Culture Collection, Rockville, MD and assigned ATCC No. 9892.